Krakow, Poland – 4 April 2019 – Selvita (WSE:SLV), a clinical stage company engaged in the research and development of novel cancer therapies, as well as provision of drug discovery and development services, will present at the upcoming 2019 HCW Global Life Sciences Conference, taking place on April 8-9 in London, UK.
The presentation will be held by Pawel Przewiezlikowski, Chief Executive Officer at Selvita, and will focus on the recent corporate events and company plans to separate into two independent, global businesses i.e. oncology therapeutics and contract research business unit, with a special focus of the presentation on the oncology division.
The presentation will take place on Monday, April 8, at 4:50 PM BT, in the Grosvenor House Hotel – North Suite.
Webcast of this presentation will also be made available: http://wsw.com/webcast/hcw4/slv/
The HCW Global Life Sciences Conference is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.
To contact Selvita’s delegates at this conference, please contact us at email@example.com
Additional information is available on the conference website at
Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways, and other cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.
+48 784 069 418